论文部分内容阅读
目的:评价生长抑素对早期急性肠梗阻患者炎性因子的表达及病程的影响。方法:选取2012年12月—2014年12月间收治的急性肠梗阻患者100例,采用抽签法将其分为对照组和观察组,每组50例;对照组患者均给予常规治疗,观察组患者在对照组基础上均给予生长抑素治疗,比较两组患者治疗后胃肠蠕动肛门排气时间、腹胀消失时间、肠鸣音恢复时间、住院时间和总体缓解时间,并观察治疗前后患者炎性因子白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平的变化。结果:观察组患者治疗后内肠蠕动肛门排气时间、腹胀消失时间、肠鸣音恢复时间、住院时间和总体缓解时间分别为(7.14±2.41)d,(4.03±1.53)d,(3.98±2.00)d,(8.05±1.01)d和(13.21±7.23)d优于对照组为(11.84±3.25)d,(7.28±3.05)d,(5.51±1.76)d,(11.50±1.05)d和(21.01±10.62)d(P<0.05);观察组患者治疗后血清TNF-α、IL-6水平分别为(50.0±4.4)ng/m L和(49.8±5.4)ng/m L低于对照组分别为(56.1±2.1)ng/m L和(56.2±4.8)ng/m L(P<0.05)。结论:采用生长抑素治疗早期急性肠梗阻患者的疗效较为显著,可降低急性肠梗阻患者炎性因子的表达,缩短了患者的住院治疗时间。
Objective: To evaluate the effect of somatostatin on the expression and duration of inflammatory factors in patients with early acute intestinal obstruction. Methods: A total of 100 patients with acute intestinal obstruction who were admitted between December 2012 and December 2014 were enrolled in this study. They were divided into control group and observation group by random sampling, 50 cases in each group. Patients in control group were given routine treatment and observation group Patients in the control group were given somatostatin treatment, the two groups of patients after treatment of gastrointestinal peristalsophageal exhaust time, disappearance of abdominal distension time, bowel sounds recovery time, length of stay and overall remission time, and observed before and after treatment of patients with inflammation Changes in the levels of interleukin - 6 (IL - 6), tumor necrosis factor - α (TNF - α). Results: The time of rectal bleeding, disappearance of abdominal distension, bowel sound recovery time, hospitalization time and total remission time in observation group were (7.14 ± 2.41) d, (4.03 ± 1.53) d and (3.98 ± (11.84 ± 3.25) d, (7.28 ± 3.05) d, (5.51 ± 1.76) d, (11.50 ± 1.05) d and (2.50 ± 1.01) d and (21.01 ± 10.62) d (P <0.05). The levels of TNF-α and IL-6 in the observation group were (50.0 ± 4.4) ng / m L and (49.8 ± 5.4) ng / m L, respectively, The groups were (56.1 ± 2.1) ng / m L and (56.2 ± 4.8) ng / m L, respectively (P <0.05). Conclusions: Therapeutic effect of somatostatin on patients with early acute intestinal obstruction is significant, which can reduce the expression of inflammatory factors and shorten the hospitalization time of patients with acute intestinal obstruction.